CLINICAL TRIALS PROFILE FOR ARIXTRA
✉ Email this page to a colleague
All Clinical Trials for ARIXTRA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00060554 ↗ | A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN) | Withdrawn | Schering-Plough | Phase 2 | 2003-04-01 | The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting. |
| NCT00256100 ↗ | Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure. | Terminated | Melbourne Health | N/A | 2004-06-01 | The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure. |
| NCT00328939 ↗ | ARIXTRA Local Study For Registration In China. | Completed | GlaxoSmithKline | Phase 3 | 2004-05-01 | This is a local registration study in China to compare the safety and efficacy of ARIXTRA to Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of components. |
| NCT00412464 ↗ | Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis | Completed | Children's Hospital Los Angeles | Phase 1 | 2006-09-01 | This study will evaluate the use of a blood thinner, fondaparinux, which is approved for use in adults (not in children) in a children aged 1-18 years. Subject with a blood clot (thrombosis) or heparin-induced thrombocytopenia who need to be on a blood thinner will be eligible to participate. Subjects will receive a once daily dose of fondaparinux followed by blood tests at 2, 4, 12, and 24 hours after the first dose in order to determine the proper dose for this age group. The hypothesis is that children receiving fondaparinux will be able to receive a once daily dose. The currently available alternative agent, enoxaparin, needs to be given twice daily. In addition, an evaluation of the safety of this medication will be made by assessing for side effects, especially bleeding. |
| NCT00423683 ↗ | Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism | Terminated | GlaxoSmithKline | Phase 3 | 2007-01-01 | The development of clots is a potentially deadly complication in many cancer patients. The current optimal treatment is unknown. Evidence supporting the effectiveness of the use of Inferior Vena Caval Filters is lacking. This study will compare the two standard of care treatment options: anticoagulation with or without a inferior vena cava filter. The anticoagulation medication chosen will be Arixtra and it will be given once a day as an injection. Patients will be called at various intervals to monitor their signs and symptoms of new thromboembolisms. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARIXTRA
Condition Name
Clinical Trial Locations for ARIXTRA
Trials by Country
Clinical Trial Progress for ARIXTRA
Clinical Trial Phase
Clinical Trial Sponsors for ARIXTRA
Sponsor Name
